




Clinical and arrhythmic outcomes after
implantation of a deﬁbrillator for primary
prevention of sudden death in patients with
post-myocardial infarction cardiomyopathy: The
Survey to Evaluate Arrhythmia Rate in High-risk
MI patients (SEARCH-MI)
Massimo Santini1*, Maurizio Russo1, Gianluca Botto2, Maurizio Lunati3,
Alessandro Proclemer4, Boris Schmidt5, Ali Erdogan6, Erhard Helmling7,
Werner Rauhe8, Martin Desaga9, Elisabetta Santi10, Marc Messier11,
and Giuseppe Boriani12
1Cardiovascular Department, San Filippo Neri Hospital, Via Martinotti, 20, 00135 Roma, Italy;
2S. Anna Hospital, Como, Italy;
3Niguarda Ca Granda Hospital, Milano, Italy;
4S. Maria
della Misericordia Hospital, Udine, Italy;
5Universitatsklinikum, Freiburg, Germany;
6Klinikum der Justus-Liebig-Universitat, Giessen, Germany;
7Westpfalzklinikum, Kaiserlautern,
Germany;
8S. Maurizio Hospital, Bolzano, Italy;
9Klinikum Dachau, Dachau, Germany;
10Medtronic Italia, Rome, Italy;
11Medtronic Bakken Research Center, Maastricht, The
Netherlands; and
12Policlinico S. Orsola-Malpighi, Bologna, Italy
Received 6 June 2008; accepted after revision 22 October 2008; online publish-ahead-of-print 9 January 2009
Aims To evaluate clinical and arrhythmic outcomes in post-infarction cardiomyopathy patients implanted with a deﬁbrilla-
tor (ICD) for primary prevention of sudden death.
Methods
and results
The SEARCH-MI registry is a European multi-centre, prospective, observational study enrolling patients after myo-
cardial infarction, chronic left ventricular dysfunction and an ICD implanted for primary prevention of sudden death.
Data on 556 patients with at least one recorded follow-up are presented. Survey to Evaluate Arrhythmia Rate in
High-risk MI (SEARCH-MI) patients were sicker than those enrolled in MADIT-II with higher New York Heart
Association class and left bundle branch block. Total mortality was 10.4%. Close to one-third (30%) of patients
experienced episodes of sustained ventricular arrhythmia. One-quarter (23%) received at least one appropriate
therapy and 10% inappropriate therapy. Gender (25% males vs. 5% females, P ¼ 0.0009) and history of non-sustained
ventricular tachycardia (24% with vs. 18% without P ¼ 0.037) were predictive of appropriate ventricular therapy.
Conclusion SEARCH-MI represents the current clinical management of post-MI patients with left ventricular dysfunction indi-
cated to deﬁbrillator implant for primary prevention. European routine clinical practice was inﬂuenced by landmark
trials and guidelines which impacted on the implantation of cardiac resynchronization therapy in over 25% of such
patients. Non-sustained ventricular tachycardia identiﬁes subjects with a higher incidence of appropriate ICD therapy.
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Patients with previous myocardial infarction (MI) and depressed
left ventricular ejection fraction (LVEF) are at increased risk of
death both from heart failure and from malignant ventricular
arrhythmias.
1 Several studies have been conducted to identify
patients at increased risk of sudden death and to improve their
clinical management.
2–7
In early 2002, the results of the MADIT-II trial were published:
this was the ﬁrst study that randomly assigned patients to
receive a deﬁbrillator or optimal medical therapy on the basis of
reduced LVEF alone. After a mean follow-up of 20 months, the
study was terminated when the pre-deﬁned reduction of 30% in
all cause mortality was reached by patients in the deﬁbrillator arm.
8
After MADIT-II investigators published their conclusions, a
debate emerged on the translation of the expected beneﬁts
from strictly controlled trial to ‘routine’ clinical practice. Because
of the potentially large number of patients eligible for this form
of therapy, there was also some concern with the ﬁnancial
burden arising from broadening indications for ICD implants.
9–12
Additional risk stratiﬁcation was sought to better target the candi-
dates for implantation, aiming to increase the cost-effectiveness of
deﬁbrillator therapy.
9,13–16 The prognostic value of several tech-
niques (microvolt T-wave alternans, QRS width, baroreﬂex sensi-
tivity tests) has been investigated without strong evidence of
beneﬁts in terms of patient selection.
17–19 Programmed ventricu-
lar stimulation also played an uncertain role in these selection as
previous studies
6,7 had enrolled patients when inducible, with no
direct comparison performed between inducible and non-inducible
subjects. The MUSTT registry
20 included also non-inducible
patients to demonstrate that inducibility was a strong risk factor
for cardiac arrest. Conclusions, however, were that non-inducible
patients were also found at increased risk, albeit a risk lower than
that observed when inducible.
The high number of deﬁbrillators implanted in the last 5 years
should provide an important source of data to compare with
MADIT-II patients.
The Survey to Evaluate Arrhythmia Rate in High-risk MI patients
(SEARCH-MI) was created in 2002 to document such a compari-
son by prospectively evaluating the arrhythmic rate, ICD interven-
tions, and adherence to trial-based recommendations on post-MI
patients in regular clinical practice. The aim of this paper is to
present the interim data on a selection of patients approximately
matching the MADIT-II enrolment criteria and to compare the
baseline characteristics and outcome of patients found during
routine clinical practice with those from the deﬁbrillator arm of
the MADIT-II population.
Methods
The SEARCH-MI registry was designed as a multi-centre, prospective,
observational study, sponsored by Medtronic. Patient enrolment
started in July 2002 (as a consequence of the MADIT-II publication)
and this interim analysis was set as of 1 October 2006 for patients
with at least one recorded follow-up beyond 70 days.
The only inclusion criteria applicable to this observational study
were those related to the MADIT-II publication:
8 MI one month or
more before entry, LVEF lower than 30%, without coronary revascu-
larization within the preceding 3 months. Exclusion criteria were:
implantation of ICD as secondary prevention of sudden death, age
,18 years, unwillingness or inability to participate in data collection,
and any condition listed as class III in guidelines for deﬁbrillator implan-
tation.
21 There was no upper age-limit.
The primary objective of this registry was to prospectively evaluate
adherence to trial-based recommendations on post-MI patients in
routine clinical practice. Arrhythmic rates, ICD intervention, and
other clinical data were collected to establish device usage and
report data on device therapy for ventricular tachyarrhythmia. A
second goal was to qualify time to the ﬁrst appropriate treatment
for ventricular arrhythmia, detailing anti-tachycardia pacing (ATP) and
the more symptomatic cardioversion shocks; cumulative percentage
of ventricular pacing (as stored in device memory); clinical events
(death due to any cause, rate, and length of hospitalizations for heart
failure).
The patients enrolled underwent deﬁbrillator implantation accord-
ing to standard techniques: single-chamber, dual-chamber, or biventri-
cular devices were implanted per treating physician prescription. All
the devices were Medtronic Inc. market-released deﬁbrillators.
Device programming was empirical. Follow-ups were scheduled and
performed according to the standard follow-up visit scheme of the
participating centres. No additional procedures beyond regular prac-
tice were required. Data on demographic and clinical characteristics
(medical history, LVEF, NYHA class, QRS width, medications, arrhyth-
mic history) were collected at baseline. At each follow-up examination,
patient related data (clinical status, NYHA class, heart failure and
other-related hospitalizations, drug therapy changes, atrial ﬁbrillation
occurrence) and device-derived data (ventricular arrhythmia docu-
mented by the ICD, ICD interventions, percentage of ventricular
pacing) were collected. Data obtained from ICD interrogation were
stored centrally on a diskette.
The cause of death was provided by the attending physician or col-
lected from clinical records. Deaths were classiﬁed according to the
following scheme:
Death occurring in the ﬁrst hour from the onset of symptoms was
deﬁned as sudden death;
22
Death resulting from a cardiac event was deﬁned as cardiac death.
Unwitnessed deaths were classiﬁed as sudden and to qualify unre-
ported mortality and patients lost to follow-up, patient’s information
was retrieved from the regional demographic service.
Ventricular arrhythmias appropriately fulﬁlling the detection criteria
of ICD devices were deﬁned as ‘sustained ventricular arrhythmias’.
This deﬁnition is different from the conventional deﬁnition of sustained
ventricular arrhythmias (i.e. tachycardia lasting more than 30 s or
causing hemodynamic collapse).
Classiﬁcation of the spontaneous episodes and ICD therapies (both
appropriate and inappropriate) stored in the device memory were
adjudicated by a committee of ﬁve physicians in a blinded review
process based on an internet platform (Web-EGM database); each
episode was independently reviewed by at least two physicians: in
the event of disagreement, a third expert contributed to the ﬁnal adju-
dication. Arrhythmic events were reported separately as appropriate
detections and appropriate therapies to avoid bias from devices pro-
grammed in the monitoring state.
The interim survival analysis of patients was based on data available
on the stated analysis cut-off date (1 October 2006) including
follow-up status, normal study termination, and reported mortality.
The protocol was approved by the local ethics committees where
required by national law and all patients gave their informed consent.
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Descriptive statistics were used to characterize the patient population.
Univariate comparisons between the baseline characteristics of the
patients, with and without ventricular tachyarrhythmia were
performed by means of the log-rank test for categorical variables
and non-parametric or parametric t-test for continuous non-Gaussian
or Gaussian variables, respectively. Relative risk and 95% conﬁdence
intervals were calculated for each categorical variable as a predictor
of life-threatening arrhythmia in the Cox regression model. Kaplan–
Meier estimates of the time from baseline to endpoints were com-
puted by means of a log-rank analysis. A value of P , 0.05 was con-
sidered signiﬁcant and no correction for multiple testing were
applied. Univariate comparisons of the baseline characteristics
between the patients enrolled in the MADIT-II trial and the
SEARCH-MI patients were made by means of the x
2 test.
Study limitations
The study has limitations inherent to its design which include its obser-
vational nature, the non-consecutive enrollment, the potential inﬂu-
ence of changing guidelines and landmark trials on the enrollment
and inclusion of the patients.
The study was a sponsored registry with data electronically col-
lected from Medtronic devices: it was not designed to provide data
from devices produced by other manufacturers. For this reason,
there is a doubt that 100% of the post-MI patients admitted in the hos-
pital with potential guideline criteria were enrolled in the study. In
addition, the study was initiated just after the publication of the
MADIT-II trial: it is highly probable that a certain number of patients
with indication to ICD implant may not have received an ICD.
The non-consecutive screening and the non-randomized design
prevent the interpretation that ICDs improved outcomes.
Results
This interim analysis covers clinical and follow-up data of 556
patients enrolled between July 2002 and October 2005. These
were derived from 48 participating centres in four countries with
the major contribution from Italy (75%), Germany (22%), Israel
(2%), and Austria (1%) completing the patient cohort. The mean
follow-up period was 17+10 months and the patients were fol-
lowed on average 4.8+2.3 times including enrollment (implant)
visit (range 1–14). Demographic and baseline data and the com-
parison with those of the ICD arm of the MADIT-II trial are
shown in Table 1.
The most signiﬁcant difference in patient characteristics is the
increased high-degree NYHA classiﬁcation (NYHA II ¼ 35% in
MADIT-II vs. 46% in SEARCH-MI, P , 0.0001; NYHA III ¼ 25%
in MADIT-II vs. 43% in SEARCH-MI, P , 0.0001) and more left
bundle branch block (LBBB) (19% in MADIT-II vs. 31% in
SEARCH-MI, P , 0.0001). SEARCH-MI patients were less likely
to have coronary artery by-pass grafting, were more frequently
treated with diuretics (86% vs. 72%, P , 0.0001) and less fre-
quently with statins (48% vs. 67%, P , 0.0001); the treatment
rate with b-blockers (P ¼ 0.014) and amiodarone (P , 0.0001)
was slightly higher in SEARCH-MI. Twenty-ﬁve per cent of
SEARCH-MI patients received a dual-chamber ICD vs. 44% in
MADIT-II (P , 0.0001); 25% of the SEARCH-MI population
received a biventricular device (such devices were not used in
the MADIT-II trial). The mean time between MI and ICD
implantation was 7.4 years, comparable to the 6.7 years reported
in MADIT-II (P ¼ 0.059).
Main clinical events
No deaths or major complications (infections, cardiac tamponade,
hemo-pneumothorax) due to the ICD implantation procedure
were reported. During follow-up, 33 patients (5.9%) had their
device replaced: 27 patients for industry recall; 4 patients for
up-grading to biventricular pacing; 2 patients for device end of life.
Total mortality was 10.4% (58 out of 556 patients); Kaplan–
Meier analysis showed a 2-years ‘all cause mortality’ of 14.4%,
close to the 16% reported by MADIT-II (P ¼ ns) (Figure 1).
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The cardiac mortality rate was 3.42% (19 out of 556 patients);
12 patients experiencing sudden death. The Kaplan–Meier esti-
mate showed a 2-year sudden cardiac death of 2.95%, compared
with the 4.9% of MADIT-II (Figure 1).
23
The mean percentage of ventricular pacing observed in
SEARCH-MI patients was 89% in the CRT group and 16% in the
non-CRT group.
Arrhythmic events
A total of 992 episodes were adjudicated as true ventricular epi-
sodes: 167 out of 556 patients (30%) presented with at least
one true ventricular arrhythmic detection. In 127 patients (23%)
at least one appropriate therapy was delivered: ATP in 85 patients
(15%) and shock in 74 patients (13%). These include 32 patients
(5.8%) which received both ATP and shock. Several patients had
multiple events. The Kaplan–Meier curves illustrate a 2-years
incidence of 31% for appropriate therapy (Figure 2). These
results are close to those observed in MADIT-II.
24
In 102 out of 556 patients (18%), a total of 516 tachyarrhythmia
episodes were inappropriately detected and stored by the ICD.
Overall, an inappropriate device therapy was delivered in 58 of
556 patients (11%), of which 32 patients (6%) received inappropri-
ate shocks.
Ventricular oversensing resulted in 26 events (8 patients) being
treated with inappropriate shock. There were 178 episodes of
inappropriately treated Atrial Tachy-arrhythmia distributed in 45
patients receiving 103 ATP and in 25 patients who received 75
inappropriate shocks.
These episodes were further classiﬁed by the expert reviewers
as Sinus Tachycardia (49 episodes, 27%), Atrial Fibrillation/ﬂutter
(74 episodes, 41%), and Atrial Tachycardia (55 episodes, 31%).
The mean cycle length of arrhythmic episodes treated by ATP
was 328+33 ms for appropriate events and 369+34 ms for
inappropriate therapy (P , 0.0001). The mean cycle length of
arrhythmic episodes treated by shock was 322+47 ms for appro-
priate interventions and was slightly longer at 350+31 ms for
inappropriate shocks (P , 0.0001).
The incidence of inappropriate device detections and therapies
may have related to device programming.
The only two baseline characteristics predictive of appropriate
deﬁbrillator therapy were gender (Figure 3) (25% incidence in
males vs. 5% in females, P ¼ 0.0009) and history of non-sustained
ventricular tachycardia (NSVT) (24% incidence in patients with
NSVT vs. 18% in patients without NSVT, P ¼ 0.037). NYHA
M. Santini et al. 478class, QRS width, history of syncope, diabetes, cumulative ventricu-
lar pacing, and LBBB were not predictive of arrhythmic events.
No differences were observed when stratiﬁed by device type
(single/dual-chamber /biventricular) for inappropriate deﬁbrillator
intervention.
Discussion
The SEARCH-MI registry represents the routine management,
between 2002 and 2005, of (mostly) Italian and German patients
with post-MI cardiomyopathy and depressed LVEF treated with
ICD for the primary prevention of sudden death. No mandatory
device selection, programming, or medical therapy was deﬁned
in the protocol. This approach is expected to complete data pub-
lished by selective, prospective, randomized clinical trials and is
able to evaluate the adherence to guidelines in medical practice.
For this reason, the data obtained by our registry have been
mainly compared with those coming from the MADIT-II study,
the ﬁrst large scale randomized clinical trial for primary prevention
of sudden death in ischaemic patients.
The incidence of ventricular tachyarrhythmia therapy is similar in
SEARCH-MI and in MADIT-II and can be interpreted as a conﬁr-
mation of the high arrhythmic risk of these patients. Notwithstand-
ing the poorer clinical status of SEARCH-MI patients, the analysis
showed a similarity in all cause mortality with the populations of
MADIT-II and of another recently published study.
25 This obser-
vation might be explained by different hypotheses: about a
quarter of the patients were treated with CRT devices while no
MADIT-II patients were treated with CRT; moreover the
SEARCH-MI registry started in 2002, 5 years after MADIT-II
started. In this time interval the clinical management of ischaemic
cardiomyopathy has improved. In the light of these important clini-
cal differences, the comparison with the MADIT-II population
should be viewed with caution.
In addition, enrolment started just after the publication of
MADIT-II trial results: at that time, according to ACC guidelines,
21
the implantation of an ICD in this setting had a class IIa (with a level
of evidence B) indication and clinicians did not extensively treat
their post-MI patients with deﬁbrillators to prevent sudden
death. The vast majority of enrolled patients received the indi-
cation to implantation mainly during hospital admission for other
causes (almost always chest pain or decompensated heart
failure): perhaps this explains the more advanced NYHA class of
registry patients compared with the MADIT-II population.
It also highlights the strength of an observational study which is
expected to follow the routine cardiology patient and reﬂect
changes in clinical practice. Hence the SEARCH-MI enrolment




Table 1 Baseline comparison between SEARCH-MI and MADIT-II (ICD arm)
MADIT-II (ICD arm) Search-MI P-value
742 patients 556 patients
Age (years) 64+10 66+10 0.00038
Male gender (%) 84 89 0.00896
Time from last MI (years)§ 6.7+6.5 7.4+7.5 0.05947
LVEF (%) 23+52 6 +6 P , 0.0001
ICD mode%VR 56 50 0.03407
DR (%) 44 25 P , 0.0001
CRT (%) 0 25 P , 0.0001
Follow-Up (months) 20+12 17+10 P , 0.0001
NYHA class distribution
NYHA class I (%) 35 9 P , 0.0001
NYHA class II (%) 35 46 P , 0.0001
NYHA class III (%) 25 43 P , 0.0001
NYHA class IV (%) 5 2 0.00449
Hypertension (%) 53 49 0.14919
Diabetes (%) 33 29 0.11829
CABG (%) 58 35 P , 0.0001
PCI (%) 45 37 0.00397
AF (permanent) (%) 9 7 0.18954
LBBB (%) 19 31 P , 0.0001
Amiodarone (%) 13* 25 P , 0.0001
Statins (%) 67* 48 P , 0.0001
Diuretics (%) 72* 86 P , 0.0001
Beta blockers (%) 70* 76 0.01426
*Comparison assumes unequal variance. Parameters for the ICD arm of MADIT-II from Moss et al.
8 except for §: the ‘Time from MI’ and standard deviation is reported from
published
38 data available for patients from both arms of the MADIT-II cohort (n ¼ 1159). *Medication Reported at last contact for MADIT-II.
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28 trials which were published in this period, along
with the amended implant guidelines.
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A total of 992 ventricular tachyarrhythmia episodes were
recorded over the 17 months follow-up period. Considering that
the time lapsed between the last MI and ICD implantation was
much longer than the study follow-up period, this ﬁnding conﬁrms
that not all ventricular tachyarrhythmia episodes should be
regarded as potentially lethal events. In support to this is the
observation that only 23% of the patients received device treat-
ment while 30% of patients showed sustained ventricular arrhyth-
mias fulﬁlling the device detection criteria. Some patients also had
VT therapy programmed off with detection programmed as
monitoring-only, up to the ﬁrst arrhythmic event. We could specu-
late that arrhythmogenic device effects should be low in view of
the low (16%) ventricular pacing observed in the non-CRT patients
during follow-up.
The evolving nature of the left ventricular remodelling process
overtime and the fact that the substrate may take time to form
may explain why devices stored such an amount of arrhythmias
after implantation; moreover, some ventricular tachyarrhythmia
would have been self-limited but lasted long enough to prompt
ICD intervention.
The incidence of inappropriate therapy in our series was com-
parable to that observed in the MADIT-II trial and was not inﬂu-
enced by the device type (dual- vs. single-chamber). Almost all
inappropriate interventions were triggered by supraventricular
tachyarrhythmia with cycle lengths signiﬁcantly longer than appro-
priately treated ones.
These observations suggest a need to tailor device program-
ming, perhaps by narrowing the VT/VF detection window and
prolonging detection time, which could help reduce inappropriate
or unnecessary ICD interventions.
The only signiﬁcant risk stratiﬁers and predictors of appropriate
ICD ﬁring were gender
30 and history of non-sustained VT before
enrolment, conﬁrming other published results.
Although ICD ﬁring and device therapies (ATP) are not con-
sidered appropriate surrogate endpoints for sudden cardiac
death, some parallel can be drawn considering the risk stratiﬁcation
markers reported in the literature.
There is conﬂicting literature on the relationship to arrhythmic
events: the fact that QRS width was not predictive of appropriate
ICD ﬁring in the SEARCH-MI comes as a conﬁrmation of many
other studies on ischaemic patients. Some comparisons may be
done with baseline characteristics of other study populations: the
PAIN-Free II sub-analysis reported no association between pro-
longed QRS duration and rapid VT/VF events
31 and a poor associ-
ation between QRS duration and SCD in the ICD-implanted arm
of the MADIT-II study,
32 whereas QRS duration was only associ-
ated to the non-device arm of the EVEREST Heart failure
study,
33 and has not been found useful for predicting all cause mor-
tality in SCD-HeFT, also following heart failure patients.
Numerous explanations come into play: as QRS duration has
been used, in the past, to select patients for implantation, there
Figure 1 SEARCH-MI registry Kaplan–Meier estimates of the
probability of survival from sudden cardiac death and all cause
mortality.
Figure 2 SEARCH-MI registry Kaplan–Meier estimates of ﬁrst
appropriate ventricular therapy and shock.
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siderable bias in the accuracy and round-off errors for these
manual measurements. In addition, QRS is only measured once
at baseline and this may not reﬂect the time-dependence and evol-
ution of the ischaemic disease.
SEARCH-MI also conﬁrms, in routine practice, that fewer
women seem to be enrolled with ICDs and that they were less
likely to experience ventricular arrhythmia, thus conﬁrming pre-
vious observations.
30–34 They seem consistent with some epide-
miological observations which point to a reduced susceptibility
of women to ventricular arrhythmia in the setting of post-MI
cardiomyopathy.
35 The lower incidence of women in these
studies is also reﬂected in the almost 3-fold higher probability of
receiving an ICD in the US centers for Medicare & Medicaid
report (1991–2005) observed in the 136 421 patients sample
from their primary prevention cohort sample.
36
The study shows that ICD implantation is very safe as previously
reported.
37 In fact, no deaths or major complications due to the
procedure were reported in the registry.
In conclusion, the observational SEARCH-MI registry demon-
strates that routine clinical practice in European patients can repli-
cate the results of therapeutic interventions observed in the more
selected MADIT-II trial populations.
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